Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Sep 7;10:109. doi: 10.1186/1476-4598-10-109

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright ©2011 Hartung et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Influence of TRAIL receptors and K_V10.1. A) DU145 cells were pre-incubated with anti-TRAIL-R1 antibody, anti-TRAIL-R2 antibody or a mixture of both for 2 h. Cells were then treated with scFv62-TRAIL in the presence of CHX (n = 2). B) DU145 cells were transfected with siRNA against TRAIL-R1 and/or TRAIL-R2 for 24 h and then treated with 50 U/ml scFv62-TRAIL in presence of 5 μg/ml CHX; apoptosis was measured by flow cytometry (n = 3). C) Quantitative real-time PCR analysis: DU145 cells were transfected with siRNA against TRAIL-R1 and/or TRAIL-R2 and analyzed for mRNA expression of death receptors. Quantitative real-time PCR analysis of D) TRAIL-R1, E) TRAIL-R2 and F) K_V10.1 expression after chemotherapeutic treatment: doxorubicin (1.8 μM), etoposide (50 μM), roscovitine (10 μM), 5-fluorouracil (100 μM).